Opsona's research and innovation
At Opsona Therapeutics our research and innovation helps prevent and treat a range of diseases such as cancers and autoimmune diseases.
The recent scientific literature suggests that tackling the initiating pathways of the innate immune system, e.g. the Toll-Like Receptors (TLRs) and the inflammasome, may lead to improved drugs for the treatment and prevention of autoimmune and inflammatory diseases.
Indeed, the potential of TLR2 as a target for therapeutic intervention is endorsed by comments from Dr Bruce Beutler, a co-recipient of the 2011 Nobel Prize in Physiology or Medicine for his pioneering work in Innate Immunity.
“If highly specific drugs capable of activating or blocking TLR2 can be designed, it might be possible to treat certain diseases with unprecedented specificity”
Opsona has the expertise, people, products and partnerships to tackle this system using highly targeted approaches.
We have strong links to leading academic centres throughout Europe and the US, giving us access to emerging technologies which have a significant impact in the field.